Scientific Publications Archives

Read more about the article ALPHA3: A Pivotal Phase 2 Study Evaluating the Safety and Efficacy of First‑Line (1L) Consolidation With Cemacabtagene Ansegedleucel (Cema‑cel) in Patients With Large B‑cell Lymphoma (LBCL) and Minimal Residual Disease (MRD) After Response to Standard Therapy

ALPHA3: A Pivotal Phase 2 Study Evaluating the Safety and Efficacy of First‑Line (1L) Consolidation With Cemacabtagene Ansegedleucel (Cema‑cel) in Patients With Large B‑cell Lymphoma (LBCL) and Minimal Residual Disease (MRD) After Response to Standard Therapy

Post author:andrewkaretas
Post published:July 15, 2024
Post category:CD19 Scientific Publications

Cellular Mechanisms Affecting Allogeneic CAR T Cell Expansion and Rejection in Large B-cell Lymphoma^*

Post author:andrewkaretas
Post published:December 11, 2023
Post category:CD19 Scientific Publications

*In collaboration with The University of Texas MD Anderson Cancer Center.

$Read more about the article ALLO‑647 for Lymphodepletion in the Allogeneic CAR T Cell Setting: Safety Experience With ALLO‑501‌ /‌ 501A in Patients With Relapsed / Refractory Large B-Cell and Follicular Lymphomas$

ALLO‑647 for Lymphodepletion in the Allogeneic CAR T Cell Setting: Safety Experience With ALLO‑501‌ /‌ 501A in Patients With Relapsed / Refractory Large B-Cell and Follicular Lymphomas

Post author:andrewkaretas
Post published:December 9, 2023
Post category:ALLO-647 Scientific Publications

Preclinical Evaluation of Allogeneic CD19 CAR T Cells Expressing an Anti-Rejection CD70 CAR

Post author:andrewkaretas
Post published:November 2, 2023
Post category:PLATFORM Scientific Publications

Read more about the article Generation of Immune-Evasive Allogeneic CAR T Cells by Inactivation of the HLA Transcriptional Regulator RFX5 and Disruption of the Immune Synapse

Generation of Immune-Evasive Allogeneic CAR T Cells by Inactivation of the HLA Transcriptional Regulator RFX5 and Disruption of the Immune Synapse

Post author:andrewkaretas
Post published:November 2, 2023
Post category:PLATFORM Scientific Publications

Preclinical Development and Characterization of Allogeneic CAR T Cells Targeting Claudin18.2 Positive Tumors

Post author:andrewkaretas
Post published:November 2, 2023
Post category:CLAUDIN Scientific Publications

Read more about the article Constitutive Turbodomains Enhance Expansion and Antitumor Activity of Allogeneic BCMA CAR T Cells in Preclinical Models

Constitutive Turbodomains Enhance Expansion and Antitumor Activity of Allogeneic BCMA CAR T Cells in Preclinical Models

Post author:andrewkaretas
Post published:August 23, 2023
Post category:BCMA Scientific Publications

$Read more about the article Presentation, Durable Responses Achieved with Anti-CD19 Allogeneic CAR T ALLO-501/501A in Phase 1 Trials of Autologous CAR T-Naïve Patients with Relapsed/Refractory Large B-Cell Lymphoma (r/r LBCL)$

Presentation, Durable Responses Achieved with Anti-CD19 Allogeneic CAR T ALLO-501/501A in Phase 1 Trials of Autologous CAR T-Naïve Patients with Relapsed/Refractory Large B-Cell Lymphoma (r/r LBCL)

Post author:andrewkaretas
Post published:June 15, 2023
Post category:CD19 Scientific Publications

$Read more about the article Poster, Durable Responses Achieved with Anti-CD19 Allogeneic CAR T ALLO-501/501A in Phase 1 Trials of Autologous CAR T-Naïve Patients with Relapsed/Refractory Large B-Cell Lymphoma (r/r LBCL)$

Poster, Durable Responses Achieved with Anti-CD19 Allogeneic CAR T ALLO-501/501A in Phase 1 Trials of Autologous CAR T-Naïve Patients with Relapsed/Refractory Large B-Cell Lymphoma (r/r LBCL)

Post author:andrewkaretas
Post published:June 13, 2023
Post category:CD19 Scientific Publications

$Read more about the article Poster, Phase 1 Results with Anti-CD19 Allogeneic CAR T ALLO-501/501A in Relapsed/Refractory Large B-Cell Lymphoma (r/r LBCL)$

Poster, Phase 1 Results with Anti-CD19 Allogeneic CAR T ALLO-501/501A in Relapsed/Refractory Large B-Cell Lymphoma (r/r LBCL)

Post author:andrewkaretas
Post published:June 12, 2023
Post category:CD19 Scientific Publications

ALPHA3: A Pivotal Phase 2 Study Evaluating the Safety and Efficacy of First‑Line (1L) Consolidation With Cemacabtagene Ansegedleucel (Cema‑cel) in Patients With Large B‑cell Lymphoma (LBCL) and Minimal Residual Disease (MRD) After Response to Standard Therapy

Cellular Mechanisms Affecting Allogeneic CAR T Cell Expansion and Rejection in Large B-cell Lymphoma^*

ALLO‑647 for Lymphodepletion in the Allogeneic CAR T Cell Setting: Safety Experience With ALLO‑501‌ /‌ 501A in Patients With Relapsed / Refractory Large B-Cell and Follicular Lymphomas

Preclinical Evaluation of Allogeneic CD19 CAR T Cells Expressing an Anti-Rejection CD70 CAR

Generation of Immune-Evasive Allogeneic CAR T Cells by Inactivation of the HLA Transcriptional Regulator RFX5 and Disruption of the Immune Synapse

Preclinical Development and Characterization of Allogeneic CAR T Cells Targeting Claudin18.2 Positive Tumors

Constitutive Turbodomains Enhance Expansion and Antitumor Activity of Allogeneic BCMA CAR T Cells in Preclinical Models

Presentation, Durable Responses Achieved with Anti-CD19 Allogeneic CAR T ALLO-501/501A in Phase 1 Trials of Autologous CAR T-Naïve Patients with Relapsed/Refractory Large B-Cell Lymphoma (r/r LBCL)

Poster, Durable Responses Achieved with Anti-CD19 Allogeneic CAR T ALLO-501/501A in Phase 1 Trials of Autologous CAR T-Naïve Patients with Relapsed/Refractory Large B-Cell Lymphoma (r/r LBCL)

Poster, Phase 1 Results with Anti-CD19 Allogeneic CAR T ALLO-501/501A in Relapsed/Refractory Large B-Cell Lymphoma (r/r LBCL)

CONNECT

CONNECT